Urethral Sparing Intensity Modulated Radiation Therapy (US-IMRT) Is Not Shown To Improve Urinary Quality of Life (QOL) in Low Risk Prostate Cancer (PCa): Results of a Randomized Phase II Trial
Jeffrey M. Vainshtein(University of Michigan), D.A. Hamstra(University of Michigan), Daniel P. Normolle(University of Michigan), Eyad Abu‐Isa(University of Michigan), C. de Pan(University of Michigan), Howard M. Sandler(Cedars-Sinai Medical Center), M.E. Ray(University of Michigan), Keith M. Olson(University of Michigan)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2011
Cited by 0
Related Papers
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
|Journal of Clinical Oncology|2008|290
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline
|Practical Radiation Oncology|2018|243
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
|Journal of Clinical Oncology|2018|179
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline
|The Journal of Urology|2019|87
Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial
|Journal of Clinical Oncology|2004|86